Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia-Reference-Cited by-同舟云学术

Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia

Published:2013-03-20 Issue:5 Volume:67 Page:412-419
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Kei A.¹,Liberopoulos E. N.¹,Mikhailidis D. P.²,Elisaf M.¹

Affiliation:

1. Department of Internal Medicine; University of Ioannina Medical School; Ioannina Greece

2. Department of Clinical Biochemistry (Vascular Disease Prevention Clinics); Royal Free Campus; University College London Medical School; University College London (UCL); London UK

Publisher

Hindawi Limited

Subject

General Medicine

Reference29 articles.

1. Dyslipidaemia;Durrington;Lancet,2003

2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report;Adult Treatment Panel III;Circulation,2002

3. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia;Kostapanos;Clin Ther,2007

4. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS);Reiner;Eur Heart J,2011

5. Guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia;Elisaf;Hellenic J Cardiol,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in glucose metabolism, C-reactive protein, and liver enzymes following intake of NAD + precursor supplementation: a systematic review and meta‐regression analysis;Nutrition & Metabolism;2024-06-24

2. Synthesis and Evaluation of Fenofibric Acid Ester Derivatives: Studies of Different Formulation with Their Bioavailability and Absorption Conditions;Journal of the Brazilian Chemical Society;2020

3. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk;Cardiovascular Diabetology;2017-05-25

4. Effect of Switch to the Highest Dose of Rosuvastatin Versus Add-on-Statin Fenofibrate Versus Add-on-Statin Nicotinic Acid/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia;Cardiovascular Therapeutics;2014-07-09

5. Drugs that Affect Lipid Metabolism;Side Effects of Drugs Annual;2014